A call for switching to a 1-dose 9vHPV national vaccination program in Ethiopia.
Tesfaye Gelanew, Liya Wondwossen, Adane Mihret, Andargachew Mulu
Author Information
- Tesfaye Gelanew: Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
- Liya Wondwossen: Federal Ministry of Health, Addis Ababa, Ethiopia.
- Adane Mihret: Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
- Andargachew Mulu: Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
No abstract text available.
- Vaccine. 2022 Mar 25;40(14):2161-2167
[PMID: 35248423]
- Front Microbiol. 2023 Feb 10;14:1116685
[PMID: 36846744]
- Lancet Glob Health. 2022 Oct;10(10):e1473-e1484
[PMID: 36113531]
- Lancet Oncol. 2021 Nov;22(11):1518-1529
[PMID: 34634254]
- NEJM Evid. 2022 Jun;1(5):EVIDoa2100056
[PMID: 35693874]
- Prev Med. 2021 Mar;144:106335
[PMID: 33678232]
- Virol J. 2020 Nov 16;17(1):179
[PMID: 33198743]
- Sci Rep. 2021 Mar 2;11(1):4954
[PMID: 33654181]
- Lancet Glob Health. 2022 Oct;10(10):e1485-e1493
[PMID: 36113532]
- PLoS One. 2022 Nov 21;17(11):e0276465
[PMID: 36409675]
- Expert Rev Vaccines. 2014 Nov;13(11):1279-90
[PMID: 25256262]
- PLoS One. 2022 Jul 13;17(7):e0271237
[PMID: 35830389]
- Virol J. 2022 Jan 15;19(1):13
[PMID: 35033141]
- Saudi Med J. 2022 May;43(5):538
[PMID: 35537734]
- J Natl Cancer Inst. 2020 Oct 1;112(10):1038-1046
[PMID: 32091594]
- Vaccine. 2023 Jan 9;41(2):372-379
[PMID: 36460537]
